Literature DB >> 24736303

Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology.

Jan Kassubek1, Hans-Peter Müller2, Kelly Del Tredici3, Johannes Brettschneider4, Elmar H Pinkhardt2, Dorothée Lulé2, Sarah Böhm2, Heiko Braak3, Albert C Ludolph2.   

Abstract

Diffusion tensor imaging can identify amyotrophic lateral sclerosis-associated patterns of brain alterations at the group level. Recently, a neuropathological staging system for amyotrophic lateral sclerosis has shown that amyotrophic lateral sclerosis may disseminate in a sequential regional pattern during four disease stages. The objective of the present study was to apply a new methodological diffusion tensor imaging-based approach to automatically analyse in vivo the fibre tracts that are prone to be involved at each neuropathological stage of amyotrophic lateral sclerosis. Two data samples, consisting of 130 diffusion tensor imaging data sets acquired at 1.5 T from 78 patients with amyotrophic lateral sclerosis and 52 control subjects; and 55 diffusion-tensor imaging data sets at 3.0 T from 33 patients with amyotrophic lateral sclerosis and 22 control subjects, were analysed by a tract of interest-based fibre tracking approach to analyse five tracts that become involved during the course of amyotrophic lateral sclerosis: the corticospinal tract (stage 1); the corticorubral and the corticopontine tracts (stage 2); the corticostriatal pathway (stage 3); the proximal portion of the perforant path (stage 4); and two reference pathways. The statistical analyses of tracts of interest showed differences between patients with amyotrophic lateral sclerosis and control subjects for all tracts. The significance level of the comparisons at the group level was lower, the higher the disease stage with corresponding involved fibre tracts. Both the clinical phenotype as assessed by the amyotrophic lateral sclerosis functional rating scale-revised and disease duration correlated significantly with the resulting staging scheme. In summary, the tract of interest-based technique allowed for individual analysis of predefined tract structures, thus making it possible to image in vivo the disease stages in amyotrophic lateral sclerosis. This approach can be used not only for individual clinical work-up purposes, but enlarges the spectrum of potential non-invasive surrogate markers as a neuroimaging-based read-out for amyotrophic lateral sclerosis studies within a clinical context.
© The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  amyotrophic lateral sclerosis; diffusion tensor imaging; fractional anisotropy; magnetic resonance imaging; motor neuron disease; staging

Mesh:

Substances:

Year:  2014        PMID: 24736303     DOI: 10.1093/brain/awu090

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  64 in total

Review 1.  [Amyotrophic lateral sclerosis. Multisystem degeneration].

Authors:  A Hübers; A C Ludolph; A Rosenbohm; E H Pinkhardt; J H Weishaupt; J Dorst
Journal:  Nervenarzt       Date:  2016-02       Impact factor: 1.214

2.  Comparison of seeding methods for visualization of the corticospinal tracts using single tensor tractography.

Authors:  Alireza Radmanesh; Amir A Zamani; Stephen Whalen; Yanmei Tie; Ralph O Suarez; Alexandra J Golby
Journal:  Clin Neurol Neurosurg       Date:  2014-12-08       Impact factor: 1.876

Review 3.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

4.  Stage-dependent remodeling of projections to motor cortex in ALS mouse model revealed by a new variant retrograde-AAV9.

Authors:  Barbara Commisso; Lingjun Ding; Karl Varadi; Martin Gorges; David Bayer; Tobias M Boeckers; Albert C Ludolph; Jan Kassubek; Oliver J Müller; Francesco Roselli
Journal:  Elife       Date:  2018-08-23       Impact factor: 8.140

Review 5.  Spreading of pathology in neurodegenerative diseases: a focus on human studies.

Authors:  Johannes Brettschneider; Kelly Del Tredici; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2015-01-15       Impact factor: 34.870

Review 6.  Hereditary Motor Neuropathies and Amyotrophic Lateral Sclerosis: a Molecular and Clinical Update.

Authors:  Rocio Garcia-Santibanez; Matthew Burford; Robert C Bucelli
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-17       Impact factor: 5.081

Review 7.  Neuroimaging as a New Diagnostic Modality in Amyotrophic Lateral Sclerosis.

Authors:  Esther Verstraete; Bradley R Foerster
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

8.  Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies.

Authors:  Pilar M Ferraro; Charles Jester; Christopher A Olm; Katerina Placek; Federica Agosta; Lauren Elman; Leo McCluskey; David J Irwin; John A Detre; Massimo Filippi; Murray Grossman; Corey T McMillan
Journal:  Neurobiol Aging       Date:  2018-04-17       Impact factor: 4.673

9.  Corticoefferent pathways in pure lower motor neuron disease: a diffusion tensor imaging study.

Authors:  Angela Rosenbohm; Hans-Peter Müller; Annemarie Hübers; Albert C Ludolph; Jan Kassubek
Journal:  J Neurol       Date:  2016-09-13       Impact factor: 4.849

10.  DnaJ/Hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins.

Authors:  Sarah N Fontaine; Dali Zheng; Jonathan J Sabbagh; Mackenzie D Martin; Dale Chaput; April Darling; Justin H Trotter; Andrew R Stothert; Bryce A Nordhues; April Lussier; Jeremy Baker; Lindsey Shelton; Mahnoor Kahn; Laura J Blair; Stanley M Stevens; Chad A Dickey
Journal:  EMBO J       Date:  2016-06-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.